Clinical Oncology
Volume 22, Issue 2 , Pages 131-135, March 2010

Radioiodine Ablation for Differentiated Thyroid Cancer—None, One Dose or Two?

  • G.J.G. Rees

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: G.J.G. Rees, Cancer Unit, Royal United Hospital, Combe Park, Bath BA1 3NG, UK. Tel: +44-7812-178901; Fax: +44-117-3179715.

Cancer Unit, Royal United Hospital, Bath, UK

Received 28 August 2009; received in revised form 12 October 2009; accepted 10 November 2009.

Abstract 

Patients with good prognosis differentiated thyroid cancer are at risk from over-treatment with radioiodine thyroid remnant ablation. Some with unfavourable localised disease might benefit from an elective second dose.

Key words: Guidelines, radioiodine, thyroid cancer

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0936-6555(09)00375-6

doi:10.1016/j.clon.2009.11.005

Clinical Oncology
Volume 22, Issue 2 , Pages 131-135, March 2010

Article Tools